A Second Near-Infrared Ru(II) Polypyridyl Complex for Synergistic Chemo-Photothermal Therapy.
Yishen LiuQianqian LiMeijia GuDisheng LuXiaoxing XiongZhiyun ZhangYanna PanYuqin LiaoQihang DingWanxia GongDean Shuailin ChenMengting GuanJunzhu WuZhiquan TianHai DengLijuan GuXuechuan HongYuling XiaoPublished in: Journal of medicinal chemistry (2022)
The clinical success of cisplatin ushered in a new era of the application of metallodrugs. When it comes to practice, however, drug resistance, tumor recurrence, and drug systemic toxicity make it implausible to completely heal the patients. Herein, we successfully transform an electron acceptor [1, 2, 5]thiadiazolo[3,4- g ]quinoxaline into a novel second near-infrared (NIR-II) fluorophore H7 . After PEGylation and chelation, HL-PEG 2k exhibits a wavelength bathochromic shift, enhanced photothermal conversion efficiency (41.77%), and an antineoplastic effect against glioma. Its potential for in vivo tumor tracking and image-guided chemo-photothermal therapy is explored. High levels of uptake and high-resolution NIR-II imaging results are thereafter obtained. The hyperthermia effect could disrupt the lysosomal membranes, which in turn aggravate the mitochondria dysfunction, arrest the cell cycle in the G2 phase, and finally lead to cancer cell apoptosis. HL-PEG 2k displays a superior biocompatibility and thus can be a potential theranostic platform to combat the growth and recurrence of tumors.
Keyphrases
- photodynamic therapy
- cell cycle
- high resolution
- cell proliferation
- fluorescence imaging
- cancer therapy
- fluorescent probe
- drug delivery
- end stage renal disease
- drug release
- oxidative stress
- newly diagnosed
- ejection fraction
- healthcare
- chronic kidney disease
- papillary thyroid
- mass spectrometry
- sensitive detection
- energy transfer
- squamous cell carcinoma
- locally advanced
- solar cells
- patient reported outcomes
- drug induced
- risk assessment
- quality improvement
- young adults
- reactive oxygen species
- single cell
- human health
- electron microscopy
- tissue engineering
- adverse drug
- childhood cancer